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ABSTRACT
BENEFITS OF PROBIOTICS CONSUMPTION IN ADULTS WITH ALLERGIC RHINITIS:
A META-ANALYSIS
by
Bochuan Xie
Background: About 1 in every 6 Americans suffer from seasonal allergies, aka allergic rhinitis
(AR), every year. Typical symptoms of AR include sneezing, stuffy nose and watery eyes.
Currently, two types of medications, anti-histamines and corticosteroids, are widely used for
relieving AR symptoms; however, in addition to the concern about drug resistance after their
long-term use, they also cause side effects such as dry mouth and dizziness.
Introduction: AR results from an abnormally heightened immune response triggered by
unharmful substances in the environment. Therefore, a therapy capable of regulating the overall
immune function of the body should alleviate the discomfort caused by AR. The intestine is the
largest immune organ of the body. And consumption of probiotics can induce positive changes in
the composition of the microbiota that reside in the intestine within a short period of time. As a
result, several trials have been conducted to investigate the therapeutic effects of probiotics on
AR. However, because of the generally small sample size of these studies, it is difficult to reach
a definite conclusion. Therefore, we performed a meta-analysis to assess if probiotics
consumption leads to improvement of AR symptoms.
Method: Key words of “probiotics” and “seasonal allergy” were used to search PubMed,
Cochrane and CINAHL to identify randomized controlled trials for the meta-analysis. Out of the
69 initially identified papers, 9 were eventually included in the analysis. Studies excluded were
either duplicates, reported un-relevant outcomes, or provided insufficient data for further
analysis. The meta-analysis was conducted through CMA 2.0, commercial comprehensive meta-

analysis software. Standardized mean difference was calculated for subjective symptoms scores
and serum biomarker levels for each study as the effect size, and the random effects model was
applied to calculate the overall effect.
Results:

As shown in the Forest plot above, the Hedges’ g value for overall symptom score was 0.451
with a p value of 0.02, indicating that probiotics consumption induced a moderate improvement
in symptoms, and the improvement is statistically significant. On the other hand, the Hedges’ g
value for blood biomarkers level was -0.15 with a p value of 0.127, meaning probiotics
performed worse than placebo at decreasing the inflammation at cellular or molecular level, as
measured by serum biomarkers, but this inferior effect was not statistically significant.
Conclusion: The use of probiotics is beneficial at relieving allergic symptoms for AR patients,
but contradictory findings were discovered when it comes to the measurement of serum
biomarkers levels. Future studies are needed to identify reliable biomarkers for AR, and studies

with similar design but larger sample size would be helpful to further investigate the
effectiveness of probiotics in the management of AR.
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Chapter I

Benefits of probiotics consumption in adults with allergic rhinitis: A MetaAnalysis

Introduction
The layman’s term of allergic rhinitis (AR) is seasonal allergies, which describes the state
of having various nasal and ocular symptoms. These symptoms occur as a result of the body’s
abnormally heightened immunological response to inhaled substances from the environment,
such as tree or grass pollen, dandruff of cats or dogs, and dust mites. In addition to causing the
physiological symptoms that are familiar to most people, e.g. itching, sneezing, runny nose,
stuffy nose, watery eyes and headaches, AR is closely associated with significant emotional
stress which negatively affects every aspect of a person’s daily life, including school, work,
exercise, as well as social life1,2. Based on a 2012 report, 10% to 20% of people living in
industrialized countries suffer from AR every year2. In the U.S., the prevalence of AR is
estimated to be 16%, translating to 40 million people3. What’s worse is that, when comparing
studies spanning the past decades, the prevalence of AR has been increasing globally2.
In people who have AR, the uncomfortable and sometimes miserable symptoms arise
because protective physiological functions are out of control. Under normal conditions, the nasal
cavity adjusts inhaled air to a comfortable temperature and level of humidity before it reaches the
lung. Such important functions are achieved thanks to the densely packed capillary network in
the nose, which establishes a highly efficient interface for heat exchange, and the seromucous
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glands located in the cavity that constantly secret mucus. Additionally, the mucus traps large
airborne particles, such as dust and pathogens, thus functioning as the first line of defense.
However, when these homeostatic and defensive functions are impaired, which is the
case in AR, characteristic allergic symptoms appear. Stuffy nose and subsequent headaches
result from the blockage of the nasal airway caused by the abnormal engorgement of the blood
vessels; runny nose is the direct effect of excessive mucus secretion4.
The development of allergic responses in the nasal cavity consists of three stages:
allergen sensitization, acute response, and chronic allergic inflammation1,4. During the first stage,
antigen presenting cells (APCs) engulf allergens upon the encounter. The allergens are then
broken down into peptide segments, which are later presented to naïve T cells (Th0 cells) once
the APCs migrate into the lymph nodes. This interaction between APCs and Th0 cells leads to
the multiplication and differentiation of Th0 cells, giving rise to either Th1 or Th2 cells. Th1
cells have been studied intensively because of their immune regulatory function. Th2 cells have
the ability to bind with B cells, triggering their transformation into plasma cells that can produce
and secret IgE into blood circulation. The high-affinity receptors on the cell membrane of mast
cells and basophils enable their capturing of the circulating IgEs. This also signifies the
completion of the stage of allergen sensitization. Whether the Th0 cells develop into Th1 cells or
Th2 cells depends on the signals they receive from both the APCs and the immediate
environment. Dendritic cells (DCs), the most thoroughly studied APCs by far, are found to play a
crucial role in this transformational process. Once again, the precursor DCs could be activated to
become either DC-1 cells or DC-2 cells, depending on the chemical signals in the vicinity. When
Th0 cells interact with DC-1 cells in an IL-12 rich environment, Th1 cells are generated. In
contrast, if the interaction taking place is between Th0 cells and DC-2 cells in an environment
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with high level of IL-4, Th2 cells are formed. High levels of Th2 cell count have been reported to
strongly relate to seasonal allergies. The second stage is acute response that initiates within
minutes after the inhalation of a previously exposed allergen. The first step is the recognition of
the allergens by the mast cells and basophils through the allergen-antibody (IgE in this case)
interaction. The subsequent binding of multiple mast cells and basophils with each single
allergen molecule leads to the cross linking between IgEs, thus opening the calcium channel of
these cells. As a result, these cells are activated and begin to release the mediators that are
packaged in the intracellular granules. Mediators involved at this step include histamine,
proteases and leukotrienes. After reaching the intracellular space, each mediator binds to its
specific receptors, which are located either on blood vessels or glands, to trigger the onset of
various symptoms. For example, binding of histamine with H1 receptors on the sensory nerve
endings quickly leads to sneezing, itching, and excessive mucus secretion. Binding of histamine
with either H1 or H2 receptors on the mucosal blood vessels causes the vessels to swell,
eventually leading to congestion. Nasal blockage and excessive discharge may also result from
the binding between leukotriene and CysLT1 or CysLT2 receptors on blood vessels and
secretary glands in the nasal cavity. Meanwhile, these mediators attract more mast cells and
basophils, causing the release of more mediators. This self-driving vicious cycle causes the
symptoms to become more and more severe. Chronic inflammation, the third stage of the
development of allergic responses, is characterized by the hyper-responsiveness of the nose to
allergens and non-allergic stimuli. At this stage, more and different types of inflammatory cells
are drawn to the sites of inflammation and become activated. These cells include, but are not
limited to, basophils, eosinophils, neutrophils, monocytes, and various T cells. The chemokines
and cytokines released not only attract more inflammatory cells, but also sustain the existing

4

inflammation, resulting in the gradual damage of the nasal epithelial cells, and consequently
increase the permeability of the nasal epithelium. Therefore, the allergens can more easily
penetrate the epithelium barrier, encounter IgE bearing cells, and trigger the following
inflammatory reactions. Moreover, the prolonged inflammation makes the nerve endings,
mucosal blood vessels, and seromucous glands more sensitive, accounting for their heightened
response to allergens and stimuli that are not allergen in nature, for instance, cold air and
smoke1,4.
The current treatment for AR includes antihistamine medication, nasal corticosteroid
sprays, nasal antihistamine sprays, and subcutaneous injection of allergens. While being able to
reduce the discomfort level of AR effectively, each therapy has its own side effects, with dry
mouth and drowsiness being the most common. Additionally, AR brings a heavy financial
burden. In 2002, it was reported that every AR patient spent on average of about $300 on
physician office visits and medication. There is also indirect financial loss associated with
absence from work5. Therefore, it is important to discover new treatments that decrease or
eliminate side effects, and are less expensive. The use of probiotics has shown such promise.
Etymologically, probiotics means “for life”6. The concept of probiotics was first
proposed in 1907 by Eli Metchnikoff, who won the Nobel Prize for his pioneering work in the
field of intestinal microecology. He stated that useful microbes and harmful microbes coexisted
in the human intestinal flora, and that it was probable to alter the flora’s composition7. In 1965,
Lilly and Still coined the term probiotics, defining substances produced by micro-organisms that
had the capability to promote the growth of other micro-organisms8. Currently, a widely
accepted definition of probiotics is the one from WHO: “live organisms when administered in
adequate amounts confer a health benefit on the host”7. The rationale of using probiotics in
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treating AR lies in the discoveries that 1) the GI tract, the largest immune organ, plays a
significant role in the regulation of immune function; 2) there are considerable differences in the
composition of the intestinal flora between AR patients and healthy individuals; and 3)
probiotics are able to change the composition of intestinal flora very quickly9.
The intestinal epithelium is the largest immune organ of the body with multiple layers
comprising its defensive system6. The first layer is a physical barrier between the environment
and the body. This barrier is formed by the tight junctions and adhesion junctions along the
lateral membranes of the epithelial cells. With fibrils made of complex lipoproteins, permeability
of these junctions can be regulated. For instance, pro-inflammatory cytokines like TNF-α can
induce the internalization of these junctions, thus disrupting the barrier. The second layer is an
antibacterial barrier established by epithelial cells and phagocytes that reside in the intestine due
to their ability to produce antimicrobial peptides. These peptides identify microbes then insert
themselves into their cell membranes, leading to the rupture and death of the microbes.
Additionally, these peptides can interfere with the metabolic and biosynthetic pathways of the
pathogens. The third line of defense is the intestinal flora, which is composed of over 400 species
with a cell count of approximately 1014. Healthy intestine flora produce organic acids and
hydrogen sulfide, forming a hostile environment to reduce the colonization of pathogens.
Moreover, the flora constantly and actively interact with the epithelial cells to regulate their
expression of antimicrobial peptides6.
The barrier functions of the intestinal epithelium are reinforced by the body’s immune
system. Gut-associated lymphoid tissue (GALT) is the largest lymphoid tissue of the body. It is
located throughout the intestine and is composed of Peyer’s patches, mesenteric lymph nodes,
and scattered lymphocytes. Cells in GALT include dendritic cells, macrophages, B cells and T

6

cells. These immune cells possess the capability to differentiate between self and pathogens
primarily through the detection of microbe-associated molecular patterns (MAMPs) on
pathogens, such as Toll-like receptors (TLRs) and nucleotide-binding oligomerization domainlike receptors (NLRs). Once pathogens are recognized, the synthesis and secretion of proinflammatory cytokines, adhesion molecules, and antimicrobial peptides in these cells and
adjacent cells are triggered, thus activating the immune defense system6.
It is hypothesized that through binding with TLRs, especially TLR-2 and TLR-9,
probiotics may initiate specific signal pathways to exert immune regulatory functions10.
Probiotics might help strengthen the junctions between epithelial cells so that the physical barrier
is less permeable to the contents such as food particles and pathogens, in the intestinal lumen. As
a result, the body is less likely to mount an abnormal immunological response10. Additionally,
damaged epithelium heals faster in the presence of probiotics10. Probiotics have also been found
to decrease the synthesis of pro-inflammatory cytokines such as IL-4, while increasing the level
of anti-inflammatory cytokines like IL-10 and IFN-γ. Probiotics are capable of suppressing the
IgE production by B cells, which might slow down the progression of AR from the onset10.
Lastly, probiotics have been reported to divert the body’s immune response to a tolerant mode.
In two in vitro studies, precursor DCs were primed to transform to DC-1 cells when cultivated
with probiotics1,4. Since DC-1 cells direct Th0 cells to develop into Th-1 cells, the cytokine
profile would be anti-inflammatory1,4.
In contrast to traditional understanding, the dysbiosis theory, a relatively new theory,
proposes that many diseases including autoimmune diseases, allergies, and inflammatory bowel
diseases result from the imbalance of microbes in the intestine flora9. This theory is supported by
the finding that the cell counts of Lactobacillus spp. and Bifidobacterium adolescentis of AR
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patients are much lower than the ones of healthy individuals. The composition of intestine flora
is greatly influenced by diet, health status, and environmental factors. The encouraging news is
that microbiota composition can be altered within 24 hours after a positive dietary change9. All
these findings strongly support the practice of dietary intervention in AR patients. It is expected
that healthy balanced intestine flora established by direct administration of probiotics, would
help the body react to inhaling allergens more mildly, thus limiting the damage caused by
inflammation. The objective of this study is to investigate if oral probiotics consumption reduces
the allergic symptoms in users compared to non-users.

Chapter II

Review of literature
Two most commonly used bacterial genera as probiotics are Lactobacillus and
Bifidobacterium, both of which are Gram-positive, produce lactic acid, and make up a large
fraction of the normal intestinal flora in humans11. Members of Lactobacillus being investigated
for potential probiotic functions include Lactobacillus acidophilus, Lactobacillus casei,
Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus spp., Lactobacillus reuteri,
Lactobacillus delbrueckii,and Lactobacillus fermentum. Members of Bifidobacterium being
studied consist of Bifidobacterium spp., Bifidobacterium longum, Bifidobacterium bifidum,
Bifidobacterium breve, Bifidobacterium lactis,and Bifidobacterium infantis11. A handful of
studies also explored the prospectively probiotics roles of other microbes; e.g., yeasts and some
E. coli strains that are not pathogenic11. Probiotics come from two major sources: natural source
and nutrition supplement. The natural source refers to different kinds of fermented foods, such as
yogurt, kefir, miso, tempeh, and sauerkraut. Probiotics supplements are packaged in various
forms: powder, capsule, and even in herbal tea. They have evolved into a multi-billion-dollar
market globally with a sale of $1.3 billion in 2010 and is predicted to reach $2.07 billion by
201512. The use of probiotics has been evaluated in several diseases characterized by abnormal
immune response. Isolauri et al. reported that the oral administration of Bifidobacterium or
Lactobacillus strains helped relieve the symptoms of food allergy13. Anaphylactic symptoms as a
result of food allergy were reduced when the probiotics mixture VSL#3 (highly potent probiotic
mixture comprising of 8 strains of live bacteria with up to 900 billion counts in one packet14) and
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Lactobacillus casei strain Shirota were consumed15. The use of probiotics have been shown to
prevent the onset of eczema16–18. Probiotics used in these studies include Lactobacillus
rhamnosus, Lactobacillus GG, Lactobacillus reuteri and Bifidobacterium lactis. The
prevalence of eczema in the control group was two times higher than that of the intervention
group16,17. Lactobacillus GG, Lactobacillus plantarum, and Bifidobacterium-12 exerted
protective effects in animal models with asthma. The probiotics reduced the allergic
inflammation of the animals’ airways19,20, and suppressed the allergen-induced degranulation of
basophils. Similar to the above diseases, AR results from abnormal allergic response. To date
researchers around the globe have conducted many studies to investigate the effects of probiotics
consumption on patients suffering from AR. However, these studies reported inconsistent results.
For example, a couple studies reported that the use of probiotics reduced the inflammation in the
patients measured by biomarkers including IgE, eosinophils, and IFN-γ, while some studies
reported the opposite21–29. Several studies showed that probiotics improved the subjective
symptoms such as nose symptom and eye symptom of the patients assessed by subjective
questionnaires, while some studies concluded that probiotics consumption did not bring about
more benefits than placebo21–29. These details are presented in the following result section.
Furthermore, most of these studies had comparatively small sample size, which limits their
capability to draw convincing conclusions. Consequently, the objective of this study is to assess
the effectiveness of probiotics consumption in treating AR through meta-analysis, and make
suggestions for future studies.

Chapter III

Methods
Inclusion criteria
A study needed to fulfill the following requirements to be included in this analysis:
double blinded, placebo-controlled trial; the participants of the studies were adults (>18 years
old); the participants had been clinically diagnosed with AR; and reported outcomes included
either subjective symptom scores and/or blood biomarker levels of IgE, eosinophils, and IFN-γ.
Search strategy
Three main databases in the field of life science (PubMed, Cochrane and CINAHL), were
searched to identify the studies to be included in the meta-analysis. The search was conducted on
February 12, 2013, as a result, it is guaranteed that even the most recently published studies are
included. Searching PubMed using MeSH words “Rhinitis, Allergic, Seasonal” and “Probiotics”
generated 27 hits. Searching Cochrane with “allergic rhinitis” and “probiotics” as “ALL TEXT”
found 37 papers. Lastly, using “CINAHL heading”, equivalent to MeSH in PubMed, the search
identified 5 articles.
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Fig. 1 Flow chart of paper selection

The process of selecting the studies to be included in the meta-analysis is shown in
Figure 1. Out of the total 69 papers, 17 papers were excluded as a result of duplication.
Seventeen more papers were excluded based on their title, primarily because the study used
animal models, or the participants were not adults. Another reason for the exclusion of some
studies based on title is that they were published in a foreign language that could not be easily
understood. Sixteen papers were further excluded based on the abstract since they did not meet
the inclusion criteria; e.g., the experiment was conducted on children or infants, or the study
reported outcomes other than subjective symptoms or blood biomarker levels like fecal microbe
composition. Lastly, after reading through the whole text, 10 additional papers were excluded
due to the fact that when reporting the outcomes of interest, they did not present data in forms
that could be used in the meta-analysis. For example, some studies presented the results as
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figures, but did not report the actual values, such as mean and SD; other studies showed the
results as ratios of post-intervention over pre-intervention measurement; and some studies simply
made a statement of not finding significant difference between the intervention group and the
placebo group, while giving no detailed values.
The general information of the 9 selected studies21–29, such as the year of the publication,
the duration of the intervention, the strain of probiotics that is used, the number of participants,
and the synopsis of the results, is summarized in Appendix 1.
Data extraction
The following information is extracted from the selected studies for the analysis: first
author and publication year, duration of the study, each outcome with respective pre- and postmeasurement of means and standard deviations for control and intervention group, sample sizes,
the dosage of the intervention, and the form of the intervention.
Statistical analysis
Comprehensive Meta-Analysis Version 2.0, commercial meta-analysis software, was
used to perform the statistical analysis. Because different methods were used to measure
outcomes in the selected studies, standardized mean difference was chosen as the effect size of
individual studies. Randomized effects model was used to calculate the overall effect size,
because of the existence of several differences among the studies: probiotic strains, varied
duration of the intervention, and inherent genetic difference of the participants. In addition, due
to the generally small sample sizes, Hedges’ g, standardized mean difference after correction,
was used for further analysis and plotting. Corresponding 95% CIs were calculated. Lastly, metaanalyses of the comparison between the placebo and probiotic groups were conducted on the
following outcomes: allergen-specific IgE, eosinophil count, IFN-γ, Th1/Th2, eye symptom
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score, nose symptom score, and overall symptom score. In studies that measured similar
outcomes, the values of measured outcomes were combined to determine the effect size. For
example, sneezing, runny nose, stuffy nose, and itchy nose were grouped together as nose
symptoms. The study by Koyama in which IgE against three different types of pollens were
measured, their values were combined during the analysis due to the similar nature of the three
measures.
Two subgroup analyses were then performed. One assessed if there was a difference in
the effects on symptoms vs. blood biomarker between placebo and probiotic groups. The other
one assessed if there were different effects between the uses of dairy vs. non-dairy as the
treatment.

Chapter IV

Results
IgE
Seven selected studies21–26,29 reported IgE as an outcome, and none of them presented a
statistically significant difference between the placebo and the probiotics group. The overall
effect barely favors the placebo group, with the overall effect size of -0.085 (Fig. 2), but is not
statistically significant. (p=0.468, Appendix 2).

Fig. 2 Meta-analysis based on the outcome of IgE
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Eosinophil
Five selected studies24–27,29 reported either eosinophil count or eosinophil % as an
outcome, and only one of the studies25 found a statistically significant difference between the
placebo and the probiotics group, with an effect size of -0.801, and a p value of 0.016 (Fig. 3).
The overall effect slightly favors the placebo group, with the overall effect size of -0.145 (Fig.
3), but is not statistically significant. (p=0.371, Appendix 3).

Fig. 3 Meta-analysis based on the outcome of eosinophil
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IFN-γ
Three selected studies21,24,26 reported IFN-γ as an outcome with one24 presenting a
statistically significant difference between the placebo and the probiotics group, with an effect
size of -1.037, and a p value of 0.006 (Fig. 4). The overall effect moderately favors the placebo
group, with the overall effect size of -0.529 (Fig. 4), which is almost statistically significant
(p=0.067, Appendix 4).

Fig. 4 Meta-analysis based on the outcome of IFN-γ
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Th1/Th2
Three selected studies22,23,25 reported Th1/Th2 as an outcome with one25 presenting a
statistically significant difference between the placebo and the probiotics group, with an effect
size of -1.865, and a p value of 0.000 (Fig. 5). The overall effect moderately favors the placebo
group, with the overall effect size of -0.535 (Fig. 5), but is not statistically significant (p=0.391,
Appendix 5).

Fig. 5 Meta-analysis based on the outcome of Th1/Th2
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Eye symptoms
Three selected studies23,24,26 reported eye-related symptom scores as outcomes, with one24
presenting a statistically significant difference between the placebo and the probiotics group,
with an effect size of 0.594, and a p value of 0.05 (Fig. 6). The overall effect moderately favors
the probiotic group, with the overall effect size of 0.35 (Fig. 6), and is statistically significant
(p=0.013, Appendix 6).

Fig. 6 Meta-analysis based on the outcome of subjective eye symptoms score
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Nose symptoms
The same three studies23,24,26 reported nose-related symptom scores as outcomes, with
one24 presenting a statistically significant difference between the placebo and the probiotic
group, with an effect size of 0.781, and a p value of 0.011 (Fig. 7). The overall effect moderately
favors the probiotic group, with the overall effect size of 0.349 (Fig. 7), and is barely statistically
significant (p=0.047, Appendix 7).

Fig. 7 Meta-analysis based on the outcome of subjective nose symptoms score
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Overall subjective symptom scores
Four selected studies23,24,26,28 reported subjective symptom scores as outcomes with
two24,28 presenting a statistically significant difference between the placebo and the probiotics
group, with an effect sizes of 0.730 and 1.315, and a p values of 0.017 and 0.023, respectively
(Fig. 8). The overall effect moderately favors the probiotic group, with the overall effect size of
0.451 (Fig. 8), and it is statistically significant (p=0.020, Appendix 8).

Fig. 8 Meta-analysis based on the outcome of overall subjective symptoms score
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Blood biomarkers vs. symptom scores
Subgroup analysis based on blood biomarkers vs. symptom scores reveals that the
placebo appeared to have induced better outcomes with regard to the measurement of blood
biomarkers, but this seemly superior effect is not statistically significant, with an overall effect
size of -0.150, and a p value of 0.127 (Fig. 9). Judging based on the subjective symptom scores,
probiotics show a statistically significantly better outcome than the placebo, with an overall
effect size of 0.451, and a p value of 0.02 (Fig. 9). And the difference between the two subgroup
analysis is statistically significant (p=0.006, Appendix 9).

Fig. 9 Subgroup analysis based on the outcome of blood biomarkers measurement
vs. subjective symptoms score
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Dairy vs. Non-dairy
Subgroup analysis based on the type of the intervention, dairy form vs. non-dairy form of
the probiotics, reveals that intervention with non-dairy form seems to have produced better
overall outcomes. The outcomes were calculated combining both blood biomarkers measurement
and subjective symptoms score. The superior effect of non-dairy intervention is not statistically
significant, with an overall effect size of 0.184, and p value of 0.200 (Fig. 10). Intervention with
dairy form actually had a worse performance than the placebo group, with an overall effect size
of -0.030, and a p value of 0.912 (Fig. 10). The difference between the two subgroup analysis is
not statistically significant (p=0.2, Appendix 10).

Fig. 10 Subgroup analysis based on the type of the intervention: dairy form vs.
non-dairy form

Chapter V

Discussion and Conclusions
The results of the meta-analysis in this study showed that the participants from the groups
consuming probiotics reported an overall lower score for subjective symptoms, compared to
those from the placebo groups, and the difference between the two groups was statistically
significant with a p value of 0.02 (Fig. 9). In other words, probiotics consumption indeed
effectively reduced the allergic symptoms. However, the observed improvement of the subjective
symptoms scores did not align with the objective measurement of the concentration of the serum
biomarkers. As a matter of fact, the results of all the objective measurements indicated an
inferior effect of the probiotics treatment than the placebo treatment, although none reached a
statistically significant level. Many reasons could potentially explain this contradiction. First of
all, the researchers might not have chosen reliable serum biomarkers. Second, even if a good
choice of biomarkers was made, the researchers might not have collected the most optimal
sample for measurement. Lastly, there reason has been debate over the merits of subjective
symptoms assessment, since widespread doubt exists in the life science field regarding the
assessment of subjective symptoms through questionnaires.
Theoretically, every molecule involved in the allergic chain reaction could be a
biomarker for the assessment of the AR status, but due to the varied biological attributes of these
molecules and the technical difficulties of the measurement, only a few have been used as
biomarkers in AR-related research studies. Even fewer of them have been evaluated for their
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validity and reproducibility. Levels of IgE, eosinophil count, Th1/Th2 ratio, and IFN-γ
concentration are parameters that have drawn the most attention.

IgE
The majority of the included studies (7 out of 9) reported IgE level as an outcome.
Unfortunately, most of these studies simply stated that the peripheral serum sample was collected
for the measurement of IgE level, while providing no further details regarding how the
measurement was taken. The remaining studies failed to mention the type of sample that was
collected for the subsequent measurement. After being captured by mast cells and basophils
through FcεRI receptors on their cell membrane, IgEs crosslink in the presence of specific
allergens, causing the degranulation of the effector cell to which they bind, which is then
followed by the progression of the allergic responses30. Based on the understanding of this vital
role of IgE in the development of AR, drugs capable of interfering with the interaction between
IgE and its effector cells have been designed to treat allergic diseases. Omalizumab, humanized
antibody against IgE, is an example. Omalizumab reduces the symptoms of allergic asthma, and
decreases the use of other traditional medications31. Therefore, IgE level possesses the attributes
of a reliable biomarker, both in theory and in practice. However, two questions need to be
answered regarding its use for assessing the severity of the AR. First, since IgE exists in the body
in two forms, cell-bound and free form, it is important to find out which one is the better marker.
Second, IgEs can be found in the blood circulation as well as in the nasal fluid discharge;
therefore, it is equally important to know which fraction of IgE is more relevant when studying
AR. The majority of IgEs tightly bind to the cell membrane of mast cells and basophils, due to
this physical connection, these IgEs exist for a long period of time. On the other hand, the freely
floating IgEs in blood circulation are not stable, having a half-life of about two days31. Therefore,
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support for choosing free-form IgE over cell-bound IgE as the biomarker seems reasonable,
because studies of AR are generally constrained by the length of the pollen season, which lasts
two to three months. This might not leave enough time for a molecule with a long life-time to
show a change. In contrast, measuring a molecule with a quick turn-over rate assesses the realtime response of the body, in this case, IgE synthesis to the intervention of probiotics
consumption. Using free-form IgEs as the biomarker has been vindicated by the finding from
studies using flow cytometry: free IgEs in the serum sample positively correlate with the
concentration of IgE-bearing monocytes and basophils31. Additionally, the technique of
measuring free IgEs in serum sample is considerably easier than measuring IgEs bound to the
effector cells.
IgE-producing cells and IgEs have been easily detected in the nasal lavage fluid that is
collected by simple techniques such as Nasal lavage (NAL) technique. In comparison, nasal
brushes (NAB), which obtains cells from the nasal mucosa, is more accurate at evaluating the
cell profile31. Plasma cells (PCs), one form of activated B cells that secret specific IgEs, reside
not only in the bone marrow but also in the respiratory mucosa31. During the pollen season, the
majority of the IgEs that are grass-pollen specific are secreted by the PCs in the respiratory
mucosa; and this de novo synthesis and secretion of pollen-specific IgEs take place throughout
the whole pollen season31. Because of the close connection between IgEs with mast cells and
basophils, measuring IgE levels at where symptoms occur, e.g. nose, should be more relevant
and more accurate at indicating the severity of the inflammation.
Eosinophils
Most of the included studies (7 out of 9) reported either eosinophil count or eosinophil %
as an outcome. In six of these seven studies, eosinophils from serum samples were counted. One
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study counted eosinophils from the nasal lavage fluid samples. None of the authors provided
details regarding how the counting was conducted. Activated eosinophil is a key effector cell
type that plays important role in maintaining the inflammation of the nasal mucosa, thus leading
to a chronic inflammatory status of the nose. Therefore, eosinophil count should be a very
informative biomarker for evaluating the severity of the nasal chronic inflammation in patients
with AR. However, it is crucial to distinguish activated eosinophils from non-activated
eosinophils. A major difference between the two is that only activated eosinophils synthesize and
present BMK13 on their cell membranes32. Researchers have also begun using eosinophil cation
protein (ECP) as a surrogate for activated eosinophils, because ECP is a soluble protein only
secreted by activated eosinophils. Along with the transition from non-pollen season to pollen
season, the level of ECP in AR patients increases dramatically. Additionally, a moderate
correlation (r=0.53) has been reported between ECP concentration and nasal symptoms during
the pollen season32. Furthermore, ECP has been measured in drug trials to evaluate the
effectiveness of the treatment. In one study, the application of fluticasone, a widely used nasal
corticosteroids spray, reduced the average ECP level of AR patients to one sixth of its starting
value. Additionally, the severity of allergic symptoms assessed by subjective symptom
questionnaires decreased by 75%32. Considering that measuring the concentration of a soluble
substance generally has much lower requirement for instruments and skills than measuring the
quantity of a certain type of cell with specific surface molecules, ECP appears to be a better
option.
Both eosinophils and ECP can be easily measured from the nasal lavage fluid. Since
eosinophils are recruited to the site of inflammation (nose in the case of AR) and function to
maintain the inflammatory status, the measurement at the local level, compared to the
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measurement in the blood, should be more sensitive at detecting the change of the severity of the
allergic symptoms caused by the intervention.
IFN-γ
A small number of the selected studies (3 out of 9) reported the measurement of IFN-γ
level from serum sample as an outcome. IFN-γ is a Th-1 specific cytokine30 that is capable of
inhibiting the transformation of Th0 to Th2 cells. Additionally, IFN-γ can suppress the
inflammatory reactions of the effector cells, including mast cells and eosinophils33. Although
many researchers conducting studies related to inflammation have measured IFN-γ level, its
applicability as a biomarkers for studies about AR has not been established. The underlying
reason might be the contradictory functions of IFN-γ. While possessing the ability to suppress
the allergic reactions, IFN-γ is a strong pro-inflammatory cytokine and a vital signal for the
activation of macrophages. Activated macrophages release highly toxic molecules, such as
oxygen radicals and nitric oxide, causing localized tissue damage30. Neither high nor low levels
of IFN-γ can indicate an improved inflammatory status of the local organ or the whole body, so
alone it would not be a good choice as a biomarker.
Th1/Th2
A small number of the selected studies (3 out of 9) reported the ratio of Th1/Th2 from
serum sample as an outcome. One study provided no details regarding the test, and the other two
reported counting cells using flow cytometry. Th1 cells were identified with CD4+, IFN-γ+, and
IL4-, while Th2 cells were identified with CD4+, IFN-γ-, and IL-4+. The cytokine profile of Th2
cells is pro-allergenic, primarily because IL-4 promotes the class switching of immunoglobulins
in B cells, giving rise to the synthesis of allergen-specific IgE. In contrast, the cytokines
produced by Th1 cells, including IFN-γ and IL-12, exert an inhibitory effect on the
transformation of Th0 cells into Th2 cells. Decreased Th2 cell count induced by immunotherapy,
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and the consequent shift of the balance from Th2 towards Th1 side, was found to be associated
with lower subjective symptoms scores and less medication use33. Nevertheless, an abnormally
skewed balance of Th1/Th2 towards the Th1 side carries its own risk of rendering individuals
vulnerable to develop contact dermatitis as the result of macrophage activation. An example of
contact dermatitis is the development of rash, sometimes even blisters, after touching poison
ivy30. Therefore, Th1/Th2 appears to be a good biomarker for studies about AR as long as it is
within a certain range. Th1 and Th2 cells play important roles at the early stage of the
development of AR, and their ratio seems to set the tone of the overall inflammatory status of the
body. Therefore, measuring the ratio is appropriate to assess potential long-term effects.
Measuring Th1/Th2 from serum sample also supports the fundamental idea behind the use
probiotics for AR management: the human body exists as an integrative entity, so an event taking
place at one part of the body has influence on other parts of the body. Generally, such effects
occur as a result of certain molecules traveling through the circulatory system. Positively altering
the composition of the microbiota in the intestine should first lead to positive changes of immune
response locally, then throughout the whole body, as a result improving diseases with abnormal
immune response in nature.
Subjective symptoms scores
Researchers in the field of life science generally are reluctant to use subjective perception
as the outcome, because these measurements indeed vary significantly between individuals, and
they cannot be objectively and repeatedly quantified. These outcomes are easily affected by
factors other than the treatment, such as mood change, energy level, and trivial things that
happen in everyday life. Probably due to these concerns, less than half of the selected studies that
are included in this analysis assessed and reported the subjective symptoms scores. If a study is a
double-blinded and placebo-controlled trial, the psychological influence due to placebo effect
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should be ruled out; moreover, interpersonal variance and mood changes are unlikely to mask or
even reverse the effects of the treatment as long as the sample size is big enough and the duration
of the intervention is long enough. Furthermore, drug trials, which have the reputation of being
rigorous, have repeatedly reported the improvement in subjective symptoms scores due to the
drug application. The intervention with probiotics consumption is conducted on people with AR
living in a real world, where confounding factors are difficult to control. What really matters to
a patient is how he/she perceives his/her quality of life. Even golden biomarkers are discovered,
the assessment of subjective symptoms still has its advantages, because human beings exist as a
inseparable entity of subjective body and objective soul.
In summary, the intervention of probiotics consumption has low risk, is cost-effective,
and is capable of decreasing symptoms and improving life quality. Therefore, Probiotics are
worth trying for AR patients who are open to alternative therapies.
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1. Summary of included studies

33

34

35

2. Test of statistical significance of IgE level between probiotics groups and placebo groups

3. Test of statistical significance of eosinophil count between probiotics groups and placebo groups

4. Test of statistical significance of IFN-γ level between probiotics groups and placebo groups
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5. Test of statistical significance of Th1/Th2 between probiotics groups and placebo groups

6. Test of statistical significance of eye symptoms score between probiotics groups and placebo groups

7. Test of statistical significance of nose symptoms score between probiotics groups and placebo groups
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8. Test of statistical significance of overall objective symptoms score between probiotics groups and placebo groups

9. Test of statistical significance of subgroup analysis of blood biomarkers level vs. symptoms score
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10. Test of statistical significance of subgroup analysis of dairy-form intervention vs. non-dairy-form intervention

